Therapeutic Confirmatory (Phase III)

3,259 trials 1,319 recruiting

Filter these 3,259 trials by condition, country, sponsor and more.

Open in Search →

MASTER Ended

2024-515404-39-00 Breast cancer 2021-01-14
"Study of chemotherapy vs immunotherapy for patients with lung cancer bounded in the thorax and completely resected" Ended

2024-513730-38-00 Resectable Non-small cell lung cancer 2021-01-13
A long-term study to assess the safety and efficacy of nemolizumab (CD14152) in subjects with prurigo nodularis (PN) Ended

2024-514502-31-00 Prurigo Nodularis 2021-01-11
An extension study to learn if Zilucoplan is safe and works over a long period in adult participants with generalized myasthenia gravis. Ended

2024-512399-37-00 Generalized Myasthenia Gravis 2020-12-29
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation Ended

2023-507263-19-00 Advanced Non-Small Cell Lung Cancer 2020-12-23
Brentuximab Vedotin plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL Ended

2023-503384-41-00 Relapsed or refractory diffuse large B-cell lymphoma (D 2020-12-22
A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy and Safety in IgG4-Related Disease. Ended

2023-508290-81-00 Immunoglobulin G4-related disease (IgG4-RD) 2020-12-18
A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in R/R DLBCL Ended

2023-504830-23-00 B-cell Lymphoma 2020-12-16
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed … Ended

2023-504959-27-00 Participants with Limited Stage-Small Cell Lung Cancer, 2020-12-09
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Pa… Ended

2023-506911-16-00 ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVAN 2020-12-04
Study of Trastuzumab Deruxtecan (DS-8201a, T-DXd) versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Ca… Ended

2024-516653-44-00 HER2-Low, Hormone Receptor Positive Breast Cancer which 2020-11-30
A Study to compare the efficacy of Risankizumab and Utsekinumab in Subjects with Moderately to Severe Active Crohns Disease Ended

2022-501645-70-00 Crohns Disease 2020-11-25
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sc… Ended

2022-502611-10-00 Primary Progressive Multiple Sclerosis (PPMS) 2020-11-24
A Combination of Acalabrutinib with R-CHOP in Subjects with previously untreated non-GCB DLBCL Ended

2023-509358-72-00 Diffuse large B-cell lymphoma 2020-11-23
A study of safety and efficacy of NBI-74788 in Classic Congenital Adrenal Hyperplasia Ended

2023-509171-16-00 Classic Congenital Adrenal Hyperplasia (CAH) 2020-11-23
Double-Blind study comparing venetoclax and azacitidine versus placebo and azacitidine in patients that are newly diagnosed with Higher-Risk… Ended

2023-507153-16-00 Higher-Risk Myelodysplastic Syndrome 2020-11-18
Apalutamide, Radiotherapy and LHRH Agonist in High-Risk Hormone-Sensitive Prostate Cancer Patients Assessed by PSMA-PET Ended

2023-505852-23-00 High risk recurrent prostate cancer previously treated 2020-11-12
A study of tucatinib vs. placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with advanced or metastatic HER2+ breast… Ended

2024-514733-38-00 Unresectable locally-advanced or metastatic HER2+ breas 2020-11-03
A Study of Atezolizumab with or without Tiragolumab in Participants with Unresectable Esophageal Squamous Cell Carcinoma whose Cancers have … Ended

2022-502052-30-00 Unresectable Esophageal Squamous Cell Carcinoma 2020-10-27
Post-operative adjuvant treatment for HPV-positive tumours Ended

2024-516673-68-00 Human papillomavirus (HPV)-positive oropharyngeal cance 2020-10-27
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sc… Ended

2023-506515-18-00 Primary Progressive Multiple Sclerosis (PPMS) 2020-10-23
Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended

2023-510390-33-00 HER2-negative breast cancer patients with high relapse 2020-10-23
Ocrelizumab VErsus Rituximab off-Label at the Onset of Relapsing MS Disease (OVERLORD-MS) Ended

2024-510716-71-00 Multiple Sclerosis 2020-10-21
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults with Relapsing Multiple Sclerosis Ended

2023-506467-34-00 Relapsing Multiple Sclerosis (MS) 2020-10-20